Market Cap
₹1,306 Cr.
P/E
14.00
About
Lincoln Pharmaceuticals Ltd is engaged in the manufacture and marketing of affordable therapeutic products. The product range of the company includes Tablets ,Capsules,Injectables,Syrups and Ointments. Read more
Lincoln Pharmaceuticals Ltd is engaged in the manufacture and marketing of affordable therapeu… Read more
Low
411
52W Range
High
754
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
14.51%
3yr Average
15.84%
5yr Average
16.41%
Net Profit Margin
Latest
14.29%
3yr Average
14.55%
5yr Average
14.05%
ROCE
Latest
18.97%
3yr Average
20.88%
5yr Average
20.86%
Debt to Equity
Latest
0.0
3yr Average
0.0
5yr Average
0.03
Market Share
0.04 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.15 %
(as of Jul 22)
Anti-Infectives - Market Share
0.80 %
(as of Nov 21)
Anti-Malarial - Market Share
0.10 %
(as of Nov 21)
Blood Related - Market Share
0.02 %
(as of Jul 22)
Cardiovascular - Market Share
0.11 %
(as of Nov 21)
Dermatology - Market Share
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    FAQs on Lincoln Pharmaceuticals Ltd. Business

    Lincoln Pharmaceuticals Ltd specializes in producing and promoting cost-effective therapeutic products such as Tablets, Capsules, Injectables, Syrups, and Ointments.

    Lincoln Pharma major competitors are Bliss GVS Pharma, Beta Drugs, Anuh Pharma, Syncom Formulations, Zota Health Care, Bharat Parenterals, Jagsonpal Pharma.
    Market Cap of Lincoln Pharma is ₹1,306 Crs.
    While the median market cap of its peers are ₹1,242 Crs.

    Lincoln Pharma seems to be less financially stable compared to its peers.
    Altman Z score of Lincoln Pharma is 8.57 and is ranked 4 out of its 8 competitors.

    Company Filing
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis